Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

NCT01556438 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: Tabalumab
DRUG: Bortezomib IV
DRUG: Bortezomib SC
DRUG: Dexamethasone

Sponsor

Eli Lilly and Company